Physician profile
Michaela Lessler
NPI 1710964275
$2,933.37
in general payments reported to CMS, 2019-2025
31 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $241 · 2021: $399 · 2022: $362 · 2023: $592 · 2024: $460 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $528.65 | 2020-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $272.52 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.86 | 2019-2025 | Jascayd |
| Genzyme Corporation | $194.26 | 2019-2025 | |
| Grifols USA, LLC | $181.63 | 2020-2024 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $163.39 | 2023-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $142.51 | 2021-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $129.49 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $125.57 | 2020-2024 | Dupixent |
| Insmed, INC. | $118.73 | 2020-2025 | Brinsupri, Arikayce |
| Covis Pharma Gmbh | $115.44 | 2021 | |
| Amgen INC. | $88.70 | 2022-2025 | Tezspire |
| Electromed, INC. | $83.28 | 2024-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $63.52 | 2020-2025 | Zerbaxa, Recarbrio |
| Astellas Pharma US INC | $63.20 | 2025 | Cresemba |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.06 | 2020-2023 | Glassia |
| Viatris Specialty LLC | $45.40 | 2025 | Yupelri |
| Viiv Healthcare Company | $44.71 | 2024-2025 | Dovato, Rukobia |
| Jazz Pharmaceuticals INC. | $42.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37.05 | 2021 | |
| Ucb, INC. | $23.39 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $22.88 | 2024 | |
| Inspire Medical Systems, INC. | $21.36 | 2025 | Inspire |
| Cmp Pharma, INC. | $21.16 | 2024 | Liqrev, Tadliq, Norliqva |
| Mayne Pharma Commercial LLC | $20.86 | 2020 | |
| Gilead Sciences, INC. | $20.20 | 2021 | |
| Circassia INC. | $20.06 | 2019 | |
| Vifor Pharma, INC. | $18.54 | 2025 | Zemaira |
| Avadel Cns Pharmaceuticals, LLC | $16.84 | 2025 | Lumryz |
| Pfizer INC. | $16.19 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Lessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.